A Nanoconjugate Apaf-1 Inhibitor Protects Mesothelial Cells from Cytokine-Induced Injury by Santamaría, Beatriz et al.
A Nanoconjugate Apaf-1 Inhibitor Protects Mesothelial
Cells from Cytokine-Induced Injury
Beatriz Santamarı´a1, Alberto Benito-Martin1, Alvaro Conrado Ucero1, Luiz Stark Aroeira2, Ana Reyero1,
Marı´a Jesu´s Vicent3, Mar Orza´ez6, Angel Celdra´n1, Jaime Esteban8, Rafael Selgas2, Marta Ruı´z-Ortega4,
Manuel Lo´pez Cabrera5, Jesu´s Egido4, Enrique Pe´rez-Paya´6,7, Alberto Ortiz1*
1Dialysis Unit, Fundacio´n Jime´nez Dı´az, Universidad Auto´noma de Madrid, Instituto Reina Sofı´a de Investigacio´n Nefrolo´gica, Madrid, Spain, 2 Servicio de Nefrologı´a,
Hospital Universitario La Paz, Madrid, Spain, 3 Polymer Therapeutics Laboratory, Department of Medicinal Chemistry, Centro de Investigacio´n Prı´ncipe Felipe, Valencia,
Spain, 4 Laboratory of Renal and Vascular Research, Universidad Auto´noma de Madrid, Madrid, Spain, 5Molecular Biology Department, Hospital Universitario de la
Princesa, Madrid, Spain, 6 Peptide and Protein Laboratory, Department of Medicinal Chemistry, Centro de Investigacio´n Prı´ncipe Felipe, Valencia, Spain, 7 Instituto de
Biomedicina de Valencia CSIC, Valencia, Spain, 8 Servicio de Microbiologı´a, Fundacio´n Jimenez Dı´az, Madrid, Spain
Abstract
Background: Inflammation may lead to tissue injury. We have studied the modulation of inflammatory milieu-induced
tissue injury, as exemplified by the mesothelium. Peritoneal dialysis is complicated by peritonitis episodes that cause loss of
mesothelium. Proinflammatory cytokines are increased in the peritoneal cavity during peritonitis episodes. However there is
scarce information on the modulation of cell death by combinations of cytokines and on the therapeutic targets to prevent
desmesothelization.
Methodology: Human mesothelial cells were cultured from effluents of stable peritoneal dialysis patients and from
omentum of non-dialysis patients. Mesothelial cell death was studied in mice with S. aureus peritonitis and in mice injected
with tumor necrosis factor alpha and interferon gamma. Tumor necrosis factor alpha and interferon gamma alone do not
induce apoptosis in cultured mesothelial cells. By contrast, the cytokine combination increased the rate of apoptosis 2 to 3-
fold over control. Cell death was associated with the activation of caspases and a pancaspase inhibitor prevented apoptosis.
Specific caspase-8 and caspase-3 inhibitors were similarly effective. Co-incubation with both cytokines also impaired
mesothelial wound healing in an in vitro model. However, inhibition of caspases did not improve wound healing and even
impaired the long-term recovery from injury. By contrast, a polymeric nanoconjugate Apaf-1 inhibitor protected from
apoptosis and allowed wound healing and long-term recovery. The Apaf-1 inhibitor also protected mesothelial cells from
inflammation-induced injury in vivo in mice.
Conclusion: Cooperation between tumor necrosis factor alpha and interferon gamma contributes to mesothelial injury and
impairs the regenerative capacity of the monolayer. Caspase inhibition attenuates mesothelial cell apoptosis but does not
facilitate regeneration. A drug targeting Apaf-1 allows protection from apoptosis as well as regeneration in the course of
inflammation-induced tissue injury.
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Introduction
Tissue injury is an unwanted adverse effect of inflammation.
Peritoneal dialysis (PD) is a renal replacement therapy modality that is
marred by episodes of bacterial infection, leading to localized
inflammation evidenced as peritonitis [1]. PD represents an
interesting model of inflammation since the technique consists of
and allows repeated non-invasive access to the peritoneal cavity,
allowing both monitoring of the inflammatory process as well as
therapy by local delivery of drugs. Currently the therapy of peritonitis
consists of local intraperitoneal delivery of antibiotics and heparin [2].
One of the main peritoneal manifestations of inflammatory tissue
injury is loss of mesothelial cells, which occurs both during chronic
PD and in acute inflammatory episodes [3,4]. Apoptotic mesothelial
cells are lost in the peritoneal effluent of stable PD patients and the
number of peritoneal effluent apoptotic mesothelial cells increases 80-
fold during peritonitis [5–7]. Counting effluent apoptotic cells will
underestimate apoptosis, since the apoptotic features have a half-life
of 1–2 hours and most apoptotic cells are engulfed by phagocytes [8].
Lethal cytokines are among the endogenous mediators that cause
mesothelial cell death [5,6,9–11]. FasL directly promotes mesothelial
cell apoptosis [6]. By contrast, neither TNF nor TRAIL alone
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modulate mesothelial cell survival [6]. However, most extracellular
inputs are not processed in isolation, rather, multiple inputs are
perceived and integrated by cells in a proinflammatory milieu [12]. In
this regard, mesothelial cells are immersed in a complex microen-
vironment and inflammatory cytokines may cooperate to influence
on mesothelial cell fate. Other inflammatory mediators, bacterial
infection, tumor cells, PD solutions and asbestos also promote
mesothelial cell apoptosis [7,11,13–18].
Apoptosis is an active model of cell death that regulates cell
number [9,19,20]. Understanding the regulation of apoptosis has
possible therapeutic relevance, since it is regulated by the activation
of intracellular lethal molecules in response to the cell microenvi-
ronment [9,19–21]. Among them, caspases are a family of
intracellular cysteine proteases that behave as activators and
effectors of apoptosis, and play a central role in the process
[20,22]. Caspase-8 is the canonical initiator caspase engaged by
lethal cytokines that activate cell death receptors. In turn, caspase-8
recruits the mitochondrial pathway for apoptosis and activates
executioner caspases, such as caspase-3, that are responsible for cell
death. Activation of the mitochondrial pathway, leads to the release
of proapoptotic molecules such as cytochrome c into the cytoplasm,
which, in the presence of dATP, induce the formation of the Apaf-1
(apoptotic protease activating factor 1)-containing macromolecular
complex called the apoptosome. This complex, in turn, binds to and
activates caspase-9. Mature caspase-9 activates effector caspases
[23]. Caspase inhibitors prevent leukocyte apoptosis induced by
conventional, glucose-containing PD solutions [6,24,25]. However,
recent reports have emphasized non-apoptotic functions of caspases
including promotion of cell proliferation that contributes to tissue
regeneration [26–28]. In addition, in certain epithelial cell types,
caspase inhibition may transform a mild proapoptotic response into
an intense necrotic response to lethal cytokines [29]. We now
explore the cooperation between inflammatory cytokines in
modulating human mesothelial cell fate and possible therapeutic
interventions to prevent mesothelial cell death during inflammation.
In particular we have analyzed its modulation by classical caspase
inhibitors as well as by targeting the activity of the apoptosome.
Recent reports have proposed the apoptosome as an interesting
target for the development of apoptosis inhibitors [30–32]. Indeed,
our results showed that chemical inhibition of apoptosome activity
with a nanoconjugate Apaf-1 inhibitor is effective in protecting
mesothelial cells from cytokine-induced apoptosis and, in contrast to
caspase inhibition, it allows wound healing and long-term recovery.
Results
Regulation of mesothelial cell apoptosis by cooperation
of inflammatory cytokines
Acute demesothelization occurs during experimental and
human peritonitis, and is associated with an increased rate of
mesothelial cell apoptosis [3–6]. During peritoneal inflammation
numerous cytokines are released locally. Among them we find
IFNc and TNFa [33,34]. Although TNFa is, by itself, a potentially
lethal cytokine [19], we did not observe a lethal effect of TNFa in
human peritoneal mesothelial cells (HPMC) cultured from the
effluent of stable PD patients (Fig. 1. A, B). IFNc increased TNFa
lethality (Fig. 1.A, B) [6]. The combination of cytokines induced
HPMC apoptosis in a time- and dose-dependent manner
(Fig. 1.B, C). By contrast, cytokines had no effect on the
percentage of cells on the S or M phase of the cell cycle, as assessed
by flow cytometry of DNA content (range 9 to 10% for the
different conditions). The combination of IFNc and TNFa also
induced apoptosis in human omental mesothelial cells (HOMC)
cultured from the omentum of non-uremic patients (Fig. 1.D).
Caspases mediate mesothelial cell apoptosis induced by
cytokine cooperation
HPMC apoptosis induced by TNFa and IFNc was characterized
by the appearance of caspase-generated fragments of cytokeratin 8/
18 in the cytoplasm and typical morphological features of nuclear
apoptosis, such as shrunk, bright and fragmented nuclei (Fig. 2.A).
Flow cytometry confirmed that TNFa and IFNc increased the
number of cells containing caspase-generated fragments of cytoker-
atin 8/18 (Fig. 2.B) and caspase-3 activity was increased by 1.760.4
fold over control at 24 h in a colorimetric assay (p,0.02, not shown).
Taken together, these data provide evidence for the involvement of
caspases in the process. In order to confirm the requirement for
caspases and to explore possible therapeutic strategies, cells were
treated with caspase inhibitors. The pan-caspase inhibitor, zVAD, or
specific caspase-3 (DEVD) or caspase-8 (IETD) inhibitors prevented
morphological features of apoptosis induced by cytokines (Fig. 2.A)
and the activation of executioner caspases (Fig. 2.A–C), and
decreased apoptosis as assessed by the presence of hypodiploid cells
(Fig. 2.D, E). Similar results were obtained in HOMC (not shown).
The most effective caspase inhibitor in decreasing the rate of
apoptosis, zVAD, was studied in further detail. In mesothelial cells
exposed to TNFa and IFNc, zVAD was unable to prevent eventual
cell death (data not shown) despite not increasing the non-apoptotic
cytotoxicity of cytokines, as it is the case with other cell types [29].
Caspase inhibition was not per se toxic in cells not exposed to cytokine
combinations and did not increase the number of dead cells staining
with trypan blue (data not shown).
Impaired wound healing in the presence of a
proinflammatory milieu is not rescued by caspase
inhibition
Acute demesothelization during peritonitis, unless very severe, is
usually a reversible response, and mesothelial cells later repopulate
the denuded area. In a wound healing system of HPMC we
studied recovery from injury in the absence of exogenous survival
factors, aiming to reproduce the adverse microenvironmental
conditions of the inflamed peritoneum. Under control conditions,
in the absence of proinflammatory cytokines, the mesothelial
covering of the wound increased over 48 h (Fig. 3.A, B). Caspase
inhibition tended to stall the process at late time points. The
continuous presence of TNFa and IFNc prevented wound
healing. Inhibition of caspases by zVAD did not rescue wound
healing among cells treated TNFa and IFNc (Fig. 3.A, B). IETD
and DEVD caspase inhibitors offered no advantage over zVAD
(not shown).
A nanoconjugate Apaf-1 inhibitor prevents cytokine-
induced apoptosis and promotes wound healing
Formation of the apoptosome is a key event in the apoptotic
signaling pathway. First-in-class polyglutamic acid (PGA)-based
Apaf-1 inhibitor nanoconjugates (PGA-peptoids) are well suited for
in vivo applications [30–32]. The PGA-peptoid QM56 prevented,
in a dose-dependent manner, mesothelial cell apoptosis induced by
a combination of cytokines, as shown for HOMC (Fig. 4.A). The
QM56 concentration chosen for the rest of the experiments
(10 mM) had an antiapoptotic activity similar to 200 mM zVAD
(Fig. 4.A). In cultured mesothelial cells QM56 prevented caspase-
3 processing induced by cytokines, as shown for HOMC (Fig. 4.B)
and completely prevented the increase in caspase 3 activity
induced by TNFa/IFNc in these cells (TNFa/IFNc 1,760.4 vs
TNFa/IFNc/QM56 0,5660.18 fold over control, p,0.03, not
shown). Similar to observations with caspase inhibitors, QM56
prevented apoptosis induced by TNFa and IFNc in mesothelial
Apaf-1 Targeting and Cytokines
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cells, as shown for HPMC (Fig. 4.C,D). QM56 did not modify
the percentage of cells in the S+M phases of the cell cycle (not
shown). By contrast to classical caspase inhibitors, QM56 restored
the wound healing capacity of mesothelial cells in the presence of
cytokines, as shown for HPMC (Fig. 5.A, B).
Apaf-1 inhibition, but not caspase inhibition, improves
long-term recovery from inflammatory injury
We next explored the potential long-term consequences of
caspase inhibition in the context of transient, short-term
inflammation. Cells were cultured for 24 to 48 h in the presence
of TNFa and IFNc with or without inhibitors and then
trypsinized, seeded in new plaques and left to recover for 5 days
in the presence of survival factors from serum but in the absence of
cytokines or inhibitors. This mimics intraperitoneal events during
the recovery from human peritonitis with an adequate response to
antibiotics. Despite the acute increase in cell death and delayed
wound healing observed in the presence of TNFa and IFNc, the
removal of these cytokines from the media and the addition of
exogenous survival factors was associated with a degree of
Figure 1. Cooperation of cytokines induces apoptosis in mesothelial cells. A) Representative flow cytometry of DNA content diagrams.
Note the increase in the hypodiploid, apoptotic population in HPMC cultured for 48 h in presence of TNFa/IFNc. B) Quantification of apoptosis in
HPMC by flow cytometry. The combination of TNFa/IFNc induces apoptosis. When not specified, 300 U/mL IFNc and 250 ng/mL TNFa were used, *
p,0.04 vs each individual cytokine at 24 h. ** p,0.001 vs each individual cytokine at 48 h. & p,0.001 vs control. Mean6SEM of 6 different
experiments. C) Dose-response in HPMC. Mean6SEM of 4 different experiments * p,0.05 vs control. D) Quantification of apoptosis in HOMC by flow
cytometry. The combination TNFa/IFNc for 48 h induces apoptosis. *p,0.005 vs. control. Mean6SEM of 4 different experiments.
doi:10.1371/journal.pone.0006634.g001
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Figure 2. Apoptosis induced by cooperation of cytokines is caspase-dependent. A) Caspase activation in HPMC exposed to TNFa/IFNc for
24 h. Apoptosis was decreased by zVAD (pan-caspase inhibitor), DEVD (caspase-3 inhibitor) and IETD (caspase-8 inhibitor). Note cytokeratin (CK) 8/18
cleavage by caspases as well as the nuclear apoptotic morphology in cells exposed to TNFa/IFNc (arrowheads). Green: FITC-M30 cytodeath antibody,
red: propidium iodide in permeabilized cells. Original magnification6100. B) Representative diagram of detection of caspase-cleaved CK 8/18 by flow
cytometry in HPMC. C) Quantification of caspase-cleaved CK 8/18 by flow cytometry in HPMC treated with TNFa and IFNc for 24 h. * p,0.005 vs
control and# p,0.05 vs TNFa/IFNc. Mean6SEM of 4 different experiments. D) Flow cytometry diagrams of permeabilized, propidium iodide-stained
cells. Note the decrement of hypodiploid cells (arrowhead) in the presence of caspase inhibitors in HPMC. E) Quantification of apoptosis by flow
cytometry of DNA content in HPMC exposed to TNFa/IFNc for 48 h. Apoptosis was decreased by zVAD, DEVD and IETD. *p,0.001 vs control and #
p,0.0005 vs TNFa/IFNc. Mean6SEM of 6 independent experiments.
doi:10.1371/journal.pone.0006634.g002
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recovery close to that obtained in control HPMC (Fig. 6.A). The
initial presence of the cytokine combination and the pan-caspase
inhibitor led to a reduced final cell number, suggesting loss of
regenerative potential (Fig. 6.A). Similar results were observed in
HOMC from non-dialysis patients (Fig. 6.B,C). Short-term
exposure of control cells to zVAD did not impair long-term
Figure 3. Inflammatory cytokines retard remesothelization. A) Wound healing in HPMC. Contrast phase microscopy. Cells were preincubated
with caspase inhibitor or vehicle and cultured in presence of proinflammatory TNFa/IFNc or control media. Original magnification 206. B)
Quantification of wound healing as number of HPMC cells filling the denuded area (cells/mm2). In presence of cytokines there is delayed wound
healing that is not improved by zVAD.* p,0.03 control vs. TNFa/IFNc and control vs TNFa/IFNc/zVAD. Mean6SEM of 5 different experiments.
doi:10.1371/journal.pone.0006634.g003
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Figure 4. A nanoconjugate Apaf-1 inhibitor (PGA-peptoid QM56) inhibits caspase activation and apoptosis. A) Quantification of
apoptosis in HOMC by flow cytometry. HOMC were preincubated with different concentrations of inhibitors or vehicle and cultured with TNFa and
IFNc for 48 hours. Mean6SEM of 3 different experiments *p,0.001vs TNFa/IFNc. B) QM56 prevents procaspase-3 processing and the appearance of
active p17 and p19 caspase-3 fragments 24 h following exposure to TNFa/IFNc in HOMC. zVAD stalled the process of caspase activation at the level
of the p21 precursor as previously described [73,74]. Binding of zVAD.fmk to this p21 intermediate blocks its activity [74]. Western blot, representative
of 3 independent experiments. C) Representative flow cytometry of DNA content diagrams. Cells were preincubated with QM56 and then cultured
with TNFa/IFNc for 48 h. Note the decreased number of hypodiploid apoptotic HPMC in TNFa/IFNc/QM56 treated cells (black arrow). Inset: nuclear
apoptotic morphology in cells exposed to TNFa/IFNc and stained with DAPI (white arrows). D) Quantification of apoptosis by flow cytometry of DNA
content in HPMC. Mean6SEM of 6 different experiments. *p,0.002 vs cells treated with TNFa/IFNc/QM56.
doi:10.1371/journal.pone.0006634.g004
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recovery, indicating that this is not an intrinsic toxic effect of
zVAD (Fig. 6.C).
By contrast to caspase inhibition, QM56 did not impair the
long-term regeneration of HPMC or HOMC subjected to an
inflammatory milieu (Fig. 6A–C). Indeed, QM56 significantly
improved recovery (Fig. 6.C).
Apaf-1 inhibitor protects from inflammation-induced
apoptosis in vivo
We next explored the potential of QM56 to modulate cell injury
in vivo. Cytokeratin fragmentation, a marker of apoptosis that
precedes nuclear changes [7], was chosen because in vivo early
apoptotic cells are rapidly expelled from cell monolayers and
Figure 5. QM56 preserves remesothelization. A) Wound healing in HPMC. Contrast phase microscopy. Cells were preincubated with Apaf-1
inhibitor and cultured in presence of proinflammatory medium (TNFa and IFNc). Original magnification 206. B) Quantification of wound healing in
HPMC as number of cells filling the denuded area (cells/mm2). The delayed wound healing induced by TNFa/IFNc is recovered in presence of QM56. *
p,0.03 control vs. TNFa/IFNc ** p,0.003 TNFa/IFNc/QM56 vs. TNFa/IFNc. Mean6SEM of 5 different experiments.
doi:10.1371/journal.pone.0006634.g005
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engulfed by professional phagocytes [35]. In mice the intraperi-
toneal administration of TNFa and IFNc resulted in an increased
rate of mesothelial cell apoptosis at 48 h (Fig. 7). S. aureus
peritonitis also resulted in mesothelial cell apoptosis (Fig. 8). The
Apaf-1 inhibitor QM56 prevented mesothelial cells apoptosis
induced by both inflammatory milieus in vivo (Fig. 7, 8).
Discussion
We chose mesothelial cell injury as a model for inflammation-
induced tissue injury because mesothelial cell loss is a clinical
problem in PD. In addition, the easy access to the peritoneal cavity
allows the local delivery of therapeutic agents. We now report that
in inflammation-induced mesothelial cell injury cytokines cooper-
ate to induce apoptosis in primary cultures of mesothelial cells
obtained from either PD patients or non-uremic individuals. We
have further explored possible therapeutic strategies to prevent cell
injury and have identified Apaf-1 inhibition as a novel approach
that prevents acute inflammation-induced mesothelial cell injury
and allows recovery.
Mesothelial cells are lost by apoptosis in the course of human
bacterial PD peritonitis [5–7]. We now observed an increased
Figure 6. Caspase inhibition compromises long-term recovery from inflammatory injury while Apaf-1 inhibition does not. A) HPMC
plated on twelve-well plates were preincubated with inhibitors or vehicle and exposed to TNFa/IFNc for 24 h. Cells were then trypsinized, washed,
and seeded in Petri dishes in the presence of complete medium with 20% FCS for 5 days, but without cytokines or inhibitors, to allow for their
recovery. Cells were stained with crystal violet after 5 days. Representative of 3 different experiments. B) Similar results were obtained with HOMC.
HOMC were preincubated with inhibitors or vehicle and exposed to TNFa/IFNc for 48 h. Then the cells were trypsinized, washed and seeded without
inhibitors and cytokines for 5 days. Representative of 4 different experiments. C) Quantification of crystal violet staining in HOMC. Mean6SEM of 4
different experiments. *p,0.03 vs TNFa/IFNc; #p,0.02 vs TNFa/IFNc.
doi:10.1371/journal.pone.0006634.g006
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Figure 7. QM56 prevents mesothelial cell apoptosis induced by intraperitoneal cytokine administration in vivo. Mice were injected ip
with 250 ng/mL TNFa and 300 U/mL IFNc at time 0 and sacrificed at 48 h. QM56 or vehicle was administrated 1 h before the cytokines and 5 h later. A)
Representative images of Cytodeath (green)/propidium iodide co-staining. Note an increased number of cells with green cytoplasm indicative of
caspase-mediated apoptosis in the sample from the mouse injected with TNFa/IFNc. Magnification6120 B) Quantification of positive cells (green) using
Image Pro plus software in 5 fields per mouse (around 600 cells). Mean6SEM of 5 mice per group. * p,0.001 vs. control: # p,0.001vs.TNFa IFNc.
doi:10.1371/journal.pone.0006634.g007
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Figure 8. QM56 prevents mesothelial cell apoptosis during S. aureus peritonitis in mice. Mice were injected ip. with 56108 c.f.u. S. aureus
at time 0 and sacrificed at 48 h. QM56 or vehicle was administrated 1 h before the S. aureus and 5 h later A) Representative images of Cytodeath
(green)/propidium iodide co-staining. Note an increased number of cells with green cytoplasm (arrows) indicative of caspase-mediated apoptosis in
the sample from the mouse injected with S. aureus. Apoptosis was prevented by QM56 Magnification6120. B) Quantification of cytodeath positive
cells (green) using Image Pro plus software in 5 fields per mouse (around 600 cells). Mean6SEM of 5 mice per group. * p,0.05 vs control.
doi:10.1371/journal.pone.0006634.g008
Apaf-1 Targeting and Cytokines
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mesothelial apoptosis rate in an experimental model of bacterial
peritonitis. In the course of peritonitis multiple inflammatory
mediators are released locally, including IFNc and TNFa
[33,34,36,37]. Interestingly, the highest peritoneal IFNc and
TNFa levels are found in peritonitis caused by highly virulent
microorganisms, such as S. aureus, precisely the ones that cause
more severe demesothelization and that may lead to irreversible
peritoneal injury after a single, severe peritonitis episode [33,34].
Since multiple inputs are perceived by cells in a proinflammatory
milieu, it is relevant to study the actions of cytokine combinations
[12]. Our studies show that a TNFa/IFNc combination promoted
apoptosis of cultured mesothelial cells, and explore novel
therapeutic approaches to prevent inflammation-induced tissue
injury that do not target TNFa or IFNc. Both TNFa and IFNc
are required for an effective antibacterial defense. TNFa
antagonists have been marred by an increased rate of severe
infections [38]. This is more obvious with infliximab, which also
inhibits IFNc secretion [38] [39]. This suggests that during
infection rather than antagonize cytokines, we should strive for the
selective therapeutic manipulation of their specific adverse effects
that promote tissue injury, such as parenchymal cell apoptosis.
A single episode of very severe peritonitis may cause irreversible
demesothelization and peritoneal fibrosis. However, more often
peritonitis is mild to severe, and is followed by partial or total
recovery of mesothelial integrity. Both the magnitude of the initial
acute loss of mesothelium and the ability of cells to regenerate are
important factors in the recovery phase. Our experimental design
has addressed how therapeutic agents modulate the initial lethal
response to inflammation, the subsequent ability of the mesothe-
lium to repopulate a demesothelized area in the presence of
ongoing adverse microenvironmental conditions, and the later
recovery phase taking place under a milder microenvironment.
The continuous presence of inflammatory cytokines increased the
rate of apoptosis and impaired regeneration of the mesothelial
layer. However, restoration of the normal cell milieu, with
disappearance of inflammatory cytokines and the renewed
presence of survival factors, lead to recovery. We now show that
cytokine-mediated mesothelial cell apoptosis depends on caspase
activation and is prevented by caspase inhibition. However,
caspase inhibition did not allow mesothelial layer regeneration in
the presence of cytokines to proceed, and, more ominously,
severely impaired the long-term regeneration of the mesothelium
once cytokines were removed. There are several possible
explanations for this phenomenon. First, massive induction of
necrosis may occur in cells exposed to members of the TNF
superfamily when caspases are inhibited [12,29,40]. In this regard,
caspase inhibitors did not transform a moderate degree of
mesothelial cell apoptosis into a catastrophic rate of necrosis, as
zVAD/TNFa/IFNc did not increase the percentage of necrotic
cells over TNFa/IFNc. However, caspase inhibition may not
prevent eventual non-apoptotic death in cells rescued from
apoptosis. Second, caspase inhibitors may inhibit non-apoptotic
roles of caspases [41]. Cell migration and mitosis are required to
repair a cell monolayer wound [42]. Recently a spate of non-
apoptotic caspase actions on cell proliferation and migration have
been described that favor the recovery process [26–28,43,44]. As
an example, TNFa is deleterious for the liver in the course of
inflammation, through induction of apoptosis [45,46]. However,
liver regeneration following partial hepatectomy requires TNFa
signaling through the TNFR-1 receptor and caspase-8 activation
that primes hepatocytes to respond to mitogens [26,47,48].
Caspase-3 and caspase- 11 may promote cell migration [27,28].
Chemical inhibition of Apaf-1 by a nanoconjugate molecule
[30,31,49] prevented mesothelial cell apoptosis induced by the
combination of cytokines in cell culture and in vivo, suggesting
that Apaf-1 is required for mesothelial cell death to occur. This
suggests that mitochondria are engaged during TNF-induced
mesothelial cell apoptosis and, thus, that mesothelial cells should
be considered type II with regard to their response to death
receptor activation [50–53]. Following release of cytochrome c
from mitochondria, Apaf-1 is required for caspase-9 activation,
setting in motion a rapid amplification of the death signal
through activation of caspase-3 and downstream caspases
leading to further mitochondrial injury [54–56]. Contrary to
caspase inhibitors, the inhibitor of Apaf-1 also restored the
wound healing capacity and promoted long-term recovery of
mesothelium. Two, non-mutually exclusive hypothesis, might
explain the differences observed between caspase and Apaf-1
inhibitors. In one of them additional functions of caspases,
resulting from caspase activation not mediated by proapoptotic
stimuli, and, thus, not targeted by inhibition of Apaf-1, may
explain the differences. In the previous paragraph we mentioned
several non-apoptotic functions of caspases that may not be
targeted by the Apaf-1 inhibitor. In addition, as an example, in
the absence of cellular stress human glioblastoma cells exhibit a
constitutive activation of caspases in vivo and in vitro. Basal
caspase 3 and caspase 8 activity promotes migration and
invasiveness in glioblastoma cells and inhibition of caspases
decreases the migration and the invasiveness of cells [57]. The
administration of low doses of caspase inhibitors may block
glioma cell motility without affecting the execution of apoptotic
cell death [57]. In the second hypothesis, additional functions of
Apaf-1 inhibitors, unrelated to caspases, may underlie this
observation. For example, inhibition of the recently described
cell cycle arrest induced by Apaf-1 [58]. Although the role of
Apaf-1 in the DNA damage checkpoint may raise concerns on
the carcinogenicity of Apaf-1 targeting, life-long lack of Apaf-1
in Apaf-1-/- mice has not been reported to result in an increased
incidence of tumors [59,60]. Additional actions of the Apaf-1
inhibitor cannot be excluded, since a related compound, in
addition to inhibiting both functions of Apaf-1, also protects
mitochondria [49]. The therapeutic potential of the Apaf-1
inhibitor was confirmed in vivo, where it prevented mesothelial
cell loss induced by either TNFa/IFNc or by bacterial
peritonitis. Certain stimuli, such as osmotic stress and Staphy-
lococcus aureus promote mesothelial cell death with features of
apoptosis that is no prevented by caspase inhibitors [16,18]. It
will be interesting to test the efficacy of Apaf-1 inhibitors in
preventing cell death in these models.
In this paper we have focused on the monomicrobial peritonitis
characteristic of PD as a proof-of-concept model. In humans these
peritonitis are routinely treated by the intraperitoneal administra-
tion of therapeutic agents, as used in our models. Polymicrobial
peritonitis resulting from visceral perforation, as exemplified by
the cecal ligation and puncture model is also a clinically relevant
model [61]. However, intravenous therapy is used in humans with
perforated bowels, and thus would be the most relevant rout to be
studied in animals. This route presents currently unresolved
pharmacokinetic issues with the Apaf-1 inhibitor we used. Apaf-1
inhibitors should also be tested in this model in future studies.
In summary, our data indicate that a chemical compound
targeting Apaf-1 prevented inflammation-induced tissue damage,
exemplified by the peritoneum, without the adverse consequences
of approaches targeting caspases. Our data offer a word of caution
when considering the use of caspase inhibitors in the clinical
setting: the potential benefits obtained by limiting the initial
apoptosis wave may be offset by an impaired recovery from
parenchymal cell injury.
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Materials and Methods
Mesothelial cell cultures
The study was approved by the clinical ethics committee of
Fundacio´n Jime´nez Dı´az and written informed consent was
obtained. Human peritoneal mesothelial cell (HPMC) were
cultured from peritoneal effluents from 6 stable CAPD patients
as previously described [6,62]. Human omental mesothelial cells
(HOMC) were obtained from omentum from 6 non-PD patients
who underwent unrelated elective abdominal surgery [63,64].
Reagents
Human IFNc and TNFa (Peprotech, London, UK) were used at
concentrations based on prior experience with other cell types
[22,65] and expected to occur in vivo during peritonitis, specially in
patients infected with highly virulent bacteria such as S. aureus,
adjusted for PD fluid dilution [33,34]. Peritoneal effluent concen-
trations of 4.5 ng/ml TNFa and 45 U/ml IFNc have been reported
in the effluents of PD patients [33,34]. Higher cytokine concentra-
tions may be reached locally in mesothelial cells in close contact with
paracrine cytokine-secreting leukocytes, as well as in non-PD
peritonitis, which lacks the diluting effect of PD solutions. The
combination of 100 U/mL (5 ng/mL) TNFa and 20 U/mL IFNc
already increased significantly the rate of apoptosis in HOMC by 1.5
fold, but the effect increased with dose up of 250 U/mL TNFa and
300 U/mL IFNc, which were used if not otherwise specified. The
antiapoptotic polymeric nanomedicine, PGA-peptoid QM56, is the
result of the conjugation of a novel Apaf-1 inhibitor (peptoid 1) to
poly-L-glutamic acid (PGA) [30,31]. The initial dose range was
chosen based on published dose-response curves and dose-response
studies in human mesothelial cells induced to undergo apoptosis by
exposure to staurosporin (Figure S1) [30,31]. Additional dose-
response studies were performed in HOMC exposed to IFNc and
TNFa and the concentration chosen for the rest of the studies was
10 mM. The dose of caspase inhibitors was based on previous dose-
response studies [66,67]. In addition dose-response studies were
performed in HOMC exposed to IFNc and TNFa and the
concentration chosen for the rest of the studies was 200 mM zVAD.
Studies of cell death and cleavage by caspases
Mesothelial cells were cultured to subconfluence in twelve-well
plates and rested in serum-free media for 24 h. Then, IFNc and/
or TNFa were added. Cells were preincubated with apoptosis
inhibitors for 1 h. [24,68].
Apoptosis was assessed by functional and morphological studies.
Cell DNA content was quantified by flow cytometry in
permeabilized, propidium iodide-stained cells [22,65]. Permeabi-
lization allows entry of propidium iodide in all cells, dead and
alive. Apoptotic cells are characterized by a lower DNA content
(hypodiploid cells) because of nuclear fragmentation. Caspases are
key effectors of apoptosis. Evidence of caspase activation was
assessed studying caspase processing by Western blot. In addition,
flow cytometry or microscopy was used to quantify the appearance
of a specific epitope generated by caspase cleavage of cytokeratin
18 and identified by the M30 cytodeath antibody (Roche
Biochemicals, Mannheim, Germany). This epitope is generated
only in epithelial and mesothelial cells, not in leukocytes, and is not
present in native cytokeratin 18 [7,69].
For morphologic assessment of apoptosis, cells were cultured in
chamber slides (Labtek, Nunc, Naperville, IL), fixed with
methanol:acetone (1:1), and stained with DAPI [65], or FITC-
M30 cytodeath (1:250 Roche) and propidium iodide. Thus, the
typical condensed, shrunk and fragmented nuclei of apoptotic cells
were identified
Trypan blue staining of freshly collected cells was used to assess
cell death due to either apoptosis or necrosis [29].
Caspase-3 activity
HOMC were preincubated with Apaf-1 inhibitor or vehicle and
cultured with IFNc and TNFa for 24 hours. Caspase-3 activity
(MBL, Japan) was measured following the manufacturer’s
instructions. In brief, cell extracts (100 mg of protein) were
incubated in half-area 96-well plates at 37uC with 200 mM
DEVD-pNA peptide in a total volume of 100 ml. The pNA light
emission was quantified using a spectrophotometer plate reader at
405 nm. Comparison of the absorbance of pNA from an apoptotic
sample with an uninduced control allows determination of the fold
increase in caspase activity [70].
Wound healing
The wound-healing model was modified from Yung et al. [71].
Mesothelial cells were cultured to confluence in twelve-well plates
and rested in serum-free media for 24 h. The monolayer was
injured with a sterile pipette tip and IFNc, TNFa and apoptosis
inhibitors were added to serum-free media. Remesothelization was
followed for up to 48 h by marking the injured area and counting
cells inside it at different time points.
Long-term recovery
Long-term recovery was assessed by a modification of the colony-
forming assay. Cells in twelve-well plates were exposed to cytokines
and apoptosis inhibitor or vehicle for 24-48 h in serum-free media
and then trypsinized, washed, and seeded in Petri dishes in the
presence of complete medium with 20% FCS and without cytokines
or inhibitors of apoptosis. Cell number was estimated at 5 days by
crystal violet staining, absorbance was measured at 550 nm [72].
Animal model
C57BL/6 mice, 3 month-old, were injected ip with a single dose
of 300 U/mL IFNc and 250 ng/mL TNFa, or 0.5 ml PBS.
QM56 (10 mM drug-equiv.) or vehicle (0.5 ml PBS) were
administered 1 h before and 5 h later (total 4 groups, 5 mice
per group). Mice were sacrificed at 48 h. The dose and timing
were based on cell culture results.
Staphylococcus aureus ATCC 25923 (American Type Culture
Collection, Manassas, VA, USA) was used to induce peritonitis.
The experimental protocol was described previously [25] C57BL/
6 mice, 3 month-old were injected i.p. with 56108 colony forming
units (c.f.u.) S. aureus in 1 mL PBS or with PBS. At 48 hours mice
were sacrificed. Peritonitis was mild and animals had spontane-
ously cleared S. aureus by 48 h.
In both models mesenteric windows were placed on glass slides
and stained with Cytodeath and propidium iodide. Studies were
conducted in accord with the NIH Guide for the Care and Use of
Laboratory Animals.
Statistics
Statistical analysis was performed using SPSS 11.0 statistical
software. Results are expressed as mean6SEM. Significance at the
p,0.05 level was assessed by Student’s t test and one- way
ANOVA with Bonferronı´’s correction or Mann-Whitney and
Kruskal-Wallis tests.
Supporting Information
Figure S1 Quantification of apoptosis in HPMC by flow
cytometryof DNA content. HPMC were preincubated with
QM56 for 1 hour and cultured with 100 nM staurosporin(STS)
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for 24 hours. * p,0.001 vscontrol (co) or different concentrations
of inhibitor. Mean6semof 4 different experiments.
Found at: doi:10.1371/journal.pone.0006634.s001 (0.33 MB TIF)
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